Abstract
Objectives. To evaluate safety and efficacy of administering a 50/50 mixture of xenon and oxygen gases to patients with moderate-to-severe cancer pain.
Materials and methods. The study included 131 patients with moderate-to-severe cancer pain, who had been randomized into two groups: patients to receive inhalation of a mixture of xenon and oxygen in a volume ratio of 50/50, and those to receive inhalation of a mixture of oxygen and air. Efficacy was evaluated based on the following measurements: intensity of pain by NRS 30 minutes after each procedure; at the end of treatment; 2 weeks after treatment. Safety was assessed by dynamics of hemodynamic and laboratory parameters; incidence of adverse events in each group.
Results. The study results showed that the median decrease in pain intensity measured by NRS 30 minutes after inhalation of xenon-oxygen mixture was –19.00 (–24.50 to 13.25) against –4.00 (–6.00 to 2.00) in the placebo group: the results attested to statistically significant differences (p < 0.001) and a superior analgesic efficacy of xenon-oxygen mixture over placebo. Following the course of treatment, a significant NRS-measured decrease from 50.00 (40.00–60.00) to 30.00 (20.00–41.25) mm was registered in the active treatment group compared to an unverifiable decrease in NRS from 60.00 (35,00–70.00) to 55.0 (35.00–60.00) mm in the placebo group. The course of xenon inhalations made it possible to significantly reduce average daily doses of tramadol from 210.9 ± 31.3 mg to 150.1 ± 28.3, and also significantly reduce NSAID intake. AEs (n = 8) were observed only in 7 patients in the group receiving xenon therapy. Аll AEs were mild.
Conclusions. Xenon-oxygen mixture was safe and performed better than placebo for analgesia in cancer pain treatment.
References
- Reddy A., Yennurajalingam S., et al. Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist. 2013; 18: 212–220. DOI: 10.1634/theoncologist.2012-0269
- Corli O., Roberto A., Corsi N., Galli F., Pizzuto M. Opioid switching and variability in response in pain cancer patients. Supportive Care Cancer. 2019; 27(6): 2321–2327. DOI: 10.1007/s00520-018-4485-6
- Schuster M., Bayer O., Heid F., Laufenberg-Feldmann R. Opioid Rotation in Cancer Pain Treatment. Deutsches Aerzteblatt Int. 2018; 115(9): 135–142. DOI: 10.3238/arztebl.2018.0135
- Fallon M.T., Wilcock A., Kelly C.A. Oral Ketamine vs Placebo in Patients with Cancer-Related Neuropathic Pain. JAMA Oncology. 2018; 4(6): 870–872. DOI: 10.1001/jamaoncol.2018.0131
- Brockett-Walker C. The Use of Ketamine as an Adjunct to Treating Opioid Refractory Cancer-Related Pain in the Emergency Department. Adv Emerg Nurs J. 2019; 41(2): 101–106. DOI: 10.1097/tme.0000000000000244
- Буров Н.Е., Николаев Л.Л., Потапов В.Н., Козлов С.М., Коробов А.В., Потапов С.В. Технические, экономические и анестезиологические основы рециклинга медицинского ксенона. Клиническая анестезиология и реаниматология. 2008; 5(3): 32–9. [Burov N.E., Nikolaev L.L., Potapov V N., Kozlov S.M., Korobov A.V., Potapov S.V. Tekhnicheskie, ekonomicheskie i anesteziologicheskie osnovy reciklinga medicinskogo ksenona. Klinicheskaya anesteziologiya i reanimatologiya. 2008; 5(3): 32–9. (In Russ)]
- Кукушкин М.Л. и др. Обезболивающее действие ксенона у крыс на модели воспалительной боли. Бюллетень экспериментальной биологии и медицины. 2016; 161(10): 445–447. [Kukushkin M.L., et al. Obezbolivayushchee dejstvie ksenona u krys na modeli vospalitel’noj boli. Byulleten’ eksperimental’noj biologii i mediciny. 2016; 161(10): 445–447. (In Russ)]
- Holsträter T.F., Georgieff M., Föhr K.J., et al. Intranasal application of xenon reduces opioid requirement and postoperative pain in patients undergoing major abdominal surgery: a randomized controlled trial. Anesthesiology. 2011; 115(2): 398–407. DOI: 10.1097/ALN.0b013e318225cee5
- Winkler D.A., Thornton A., Farjot G., Katz I. The diverse biological properties of the chemically inert noble gases. Pharmacology Therapeutics. 2016; 160: 44–64. DOI: 10.1016/j.pharmthera.2016.02.002
- Arola O., Saraste A., Laitio R., et al. Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The Xe-Hypotheca Trial. J Am Coll Cardiol. 2017; 70(21): 2652–2660. DOI: 10.1016/j.jacc.2017.09.1088
- Weber N.C., Frässdorf J., Ratajczak C., et al. Xenon induces late cardiac preconditioning in vivo: a role forcyclooxygenase 2? Anesthesia Analgesia. 2008; 107(6): 1807–13. DOI: 10.1213/ane.Ob013e31818874bf
- Mio Y., Shim Y.H., Richards E., Bosnjak Z.J., Pagel P.S., Bienengraeber M. Xenon preconditioning: the role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats. Anesthesia Analgesia. 2009; 108(3): 858–66. DOI: 10.1213/ane.0b013e318192a520
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.